Specific activation of the lysine prodrug of aminoflavone (AFP464, NSC710464) and subsequent CYP1 metabolic activation has been observed to be particularly effective in ER-positive breast cancer cells compared with ER-negative counterparts. The gene discussed is CYP27B1; the disease is breast cancer.